On November 12, 2025, Sandoz announced a licensing agreement with EirGenix to commercialize EG1206A (pertuzumab), a proposed biosimilar of...

On November 12, 2025, Sandoz announced a licensing agreement with EirGenix to commercialize EG1206A (pertuzumab), a proposed biosimilar of...

On November 12, 2025, Sandoz announced a licensing agreement with EirGenix to commercialize EG1206A (pertuzumab), a proposed biosimilar of...

EirGenix will adopt Transcenta’s HiCB platform to support its biologics development programs and manufacturing operations.

EirGenix signs a USD 152M global deal with Sandoz for its Perjeta biosimilar EG1206A after FDA/EMA nod. Find out what this means for the HER2 drug race.

Investing.com -- Sandoz has signed a licensing deal with EirGenix to acquire commercial rights to EirGenix’s biosimilar of Perjeta (pertuzumab), the company announced Wednesday. The asset received a Phase 3 waiver in late October, positioning the product for potential filing ahead of the anticipated biosimilar market opening. Sandoz shares rose 1.5% following the announcement. This agreement strengthens Sandoz’s HER2 franchise, as the company already holds the license for EirGenix’s Herceptin biosimilar. The combination creates potential marketing synergies between the two assets. Roche, the original manufacturer of Perjeta, has previously indicated an expected biosimilar impact in fiscal year 2026. The new deal could add a commercial asset to Sandoz’s pipeline in the coming years. The acquisition may provide Sandoz with a growth source during the 2027-2028 biosimilar gap and the expected revenue slowdown, addressing concerns that investors have recently identified as a potential risk to the Sandoz investment case. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. With RO making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed RO alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including RO, could offer substantial returns as the market corrects. In 2025 alone, our AI identified several undervalued stocks that later surged by 50% or more. Is RO poised for similar growth? Don't miss the opportunity to find out.

At BIO 2026, EirGenix showcased its innovative approach in biosimilars and contract development manufacturing targeting HER2-positive breast cancer.

EirGenix has secured a global exclusive license deal with Sandoz for its HER2 biosimilar EG1206A, marking a significant milestone in oncology.

EirGenix has signed a second exclusive licensing deal with Sandoz for the HER2 biosimilar EG1206A, expanding their collaboration in oncology treatment.

EirGenix secures a global exclusive licensing agreement for biosimilar EG1206A, enhancing cancer treatment options and market presence.

EirGenix Inc. has announced a global licensing agreement with Sandoz for its HER2 biosimilar EG1206A, enhancing cancer treatment options and supporting global access.

EirGenix Inc. has announced a significant global licensing agreement with Sandoz for its HER2 biosimilar EG1206A, enhancing treatment for breast cancer patients.

On November 12, 2025, Sandoz announced a licensing agreement with EirGenix to commercialize EG1206A (pertuzumab), a proposed biosimilar of Genentech’s PERJETA® (pertuzumab).

On November 12, 2025, Sandoz announced a licensing agreement with EirGenix to commercialize EG1206A (pertuzumab), a proposed biosimilar of...

TAIPEI, 14. November 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) gab am 12. November den Abschluss eines zweiten globalen Exklusivlizenzvertrags mit dem internationalen Marktführer für Biosimilars, der Sandoz AG (SIX:SDZ/OTCQX:SDZNY), für die Vermarktung seines eigenständig...

TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast...

TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast...

EirGenixがCPHI Japan 2026に出展し、日本市場での戦略を強化。バイオシミラーやCDMOサービスの拡大に向けた取り組みを紹介します。

EirGenixがSandozと提携し、HER2陽性乳がん用バイオシミラーの商業化契約を締結。治療の選択肢が広がる。

Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing Professional audiences only. Not investment research or advice. UK readers: for persons […] The post Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing appeared first on LucidQuest Ventures.